Interleukin-1, Tumour Necrosis Factor and Treatment of the Septic Shock Syndrome
Treating the septic shock syndrome with antibodies that block only endotoxin has its limitations. Other targets for treating septic shock include neutralizing antibodies to the complement fragment C5a, platelet activating factor antagonists and blockade of endothelial cell leukocyte adhesion molecul...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/652727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Treating the septic shock syndrome with antibodies that
block only endotoxin has its limitations. Other targets for treating septic shock include neutralizing
antibodies to the complement fragment C5a, platelet activating factor antagonists and blockade of
endothelial cell leukocyte adhesion molecules. Specific blockade of the pro-inflammatory cytokines
interleukin-1 (IL-1) or tumour necrosis factor (TNF) reduces the morbidity and mortality associated with
septic shock. Moreover, blocking IL-1 and TNF likely has uses in treating diseases other than septic shock.
Use of neutralizing antibodies to TNF or IL-1 receptors has reduced the consequences of infection and
inflammation, including lethal outcomes in animal models. The IL-1 receptor antagonist, a naturally
occurring cytokine, blocks shock and death due to Escherichia coli as well as ameliorates a variety of
inflammatory diseases. Soluble TNF and IL-1 surface receptors, which bind their respective cytokines. also
ameliorate disease processes. Clinical trials are presently evaluating the safety and efficacy of anticytokine
therapies either alone or in combination. |
|---|---|
| ISSN: | 1180-2332 |